Recent advances in the genetic neuropathies

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Charcot-Marie-Tooth disease (CMT) is a common inherited neuromuscular disorder affecting 1 in 2500 individuals.
• Understanding the genetic basis and disease mechanisms of CMT is crucial for developing effective treatments.

Purpose of the Study:

• To review recent advancements in the genetics and pathomechanisms of CMT.
• To highlight how these discoveries are driving the development of rational therapeutic strategies.

Main Methods:

• Review of current literature on CMT genetics, pathomechanisms, and therapeutic targets.
• Analysis of recent preclinical and clinical findings, including biomarker identification.

Main Results:

• Identification of ErbB receptor signaling and unfolded protein response modulation as therapeutic targets for CMT1A and CMT1B, respectively.
• Vascular endothelial growth factor-mediated Nrp1 receptor stimulation identified as a target for CMT2D.
• Development of sensitive biomarkers, such as muscle MRI, for tracking disease progression.

Conclusions:

• Advances in sequencing technology, cell biology, and animal models are enabling rational CMT treatments.
• Robust natural history data and sensitive biomarkers signify a promising therapeutic era for genetic neuropathies.